Proof of concept study to investigate the efficacy, safety and tolerability as well as the pharmacokinetics and pharmacodynamics of a newly developed patch containing follicle-stimulating hormone applied after laser poration of the skin in oocyte donors compared to standard stimulation with intramuscularly/subcutaneously administered urofollitropin. A single-center, multiple dose, open label proof of concept study.

Trial Profile

Proof of concept study to investigate the efficacy, safety and tolerability as well as the pharmacokinetics and pharmacodynamics of a newly developed patch containing follicle-stimulating hormone applied after laser poration of the skin in oocyte donors compared to standard stimulation with intramuscularly/subcutaneously administered urofollitropin. A single-center, multiple dose, open label proof of concept study.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Nov 2016

At a glance

  • Drugs Urofollitropin (Primary) ; Urofollitropin (Primary)
  • Indications Infertility
  • Focus Pharmacokinetics; Proof of concept
  • Sponsors Pantec Biosolutions
  • Most Recent Events

    • 22 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top